

CLAIMS

1. A use of FK506 derivatives and β 2-agonist for manufacturing a medicament for simultaneous, separate or sequential use for treating or preventing acute or chronic asthma.
2. A method for treating or preventing acute or chronic asthma, by administering an effective amount of FK506 derivatives and β 2-agonist, simultaneously, separately or sequentially, to a human being or an animal.
3. A composition comprising FK506 derivatives and β 2-agonist as a combined preparation for treating or preventing acute or chronic asthma.
4. The use of claim 1, in which FK506 derivatives is tacrolimus or its hydrate.
5. The use of claim 1, in which β 2-agonist is salmeterol or formoterol.
6. A use of FK506 derivatives for manufacturing a medicament for treating or preventing acute or chronic asthma with β 2-agonist, simultaneously, separately or sequentially.
7. A composition comprising FK506 derivatives for treating or preventing acute or chronic asthma with β 2-agonist, simultaneously, separately or sequentially.

8. A use of $\beta 2$ -agonist for manufacturing a medicament for treating or preventing acute or chronic asthma with FK506 derivatives, simultaneously, separately or sequentially.

9. A composition comprising $\beta 2$ -agonist for treating or preventing acute or chronic asthma with FK506 derivatives, simultaneously, separately or sequentially.